Background--Haptoglobin (Hp) is an abundant plasma protein with antioxidant properties. The Hp 2-2 genotype has previously been linked to coronary heart disease risk in individuals with elevated glycosylated hemoglobin (HbA 1c ). We investigated the association of Hp and HbA 1c with cardiovascular disease (CVD) in the longitudinal, population-based Bruneck Study.
H aptoglobin (Hp) is a plasma protein that binds extracorpuscular hemoglobin (Hb) and prevents it from inflicting iron-mediated oxidative tissue damage. 1 The Hp gene has 2 major alleles, Hp1 and Hp2. Of these, the latter is a mutated version of the former and unique to humans. 2 This common polymorphism (rs72294371) leads to 3 structurally and functionally distinct proteins, Hp 1-1, 2-1, and 2-2, with reported genotype frequencies in subjects of Western European descent of 16%, 48%, and 36%. 2, 3 While Hp 1-1 forms dimers, Hp 2-1 and Hp 2-2 form larger linear and cyclic polymers, respectively. 2 Hp 2-2 was reported to be less efficient than Hp 1-1 in binding Hb and preventing oxidation by stabilizing heme iron within Hb, thereby displaying lower antioxidant activity. 4, 5 Based on these biological mechanisms, it has been suggested that the Hp 2-2 genotype may confer an elevated risk of developing cardiovascular diseases (CVD). Epidemiological studies conducted in general populations, however, have shown contradictory results. On one hand, Hp 2-2 was linked to the severity of myocardial infarction 6 and to more frequent (but less severe) peripheral arterial occlusive disease. 7 On the other hand, a large longitudinal populationbased survey has reported a %2-fold risk for coronary artery disease (CAD) death in people with the Hp 1-1 genotype. 8 Two smaller case-control studies found that the Hp 1 allele was more frequent in patients with CAD 9 and lacunar stroke, 10 compared with healthy controls. In the past years the focus has shifted towards the role of Hp genotype in CVD of diabetic patients. Because diabetes is featured by a high level of oxidative stress, relevance of the antioxidant Hp may be considerably higher in diabetic patients. 11 Actually, in a meta-analysis of 5 studies involving 1829 patients with diabetes, the pooled odds ratio (95% CI) for CVD was 2.03 (1.46, 2.81) in a comparison of the Hp 2-2 genotype with other genotypes. 12 In line with this finding, Hp 
Methods Study Population and Data Collection
The Bruneck Study is a prospective, population-based survey on the epidemiology and pathogenesis of atherosclerosis and cardiovascular disease. [15] [16] [17] [18] At baseline in 1990 the study population comprised an age-and sex-stratified random sample of all inhabitants of Bruneck (125 men and 125 women from each of the fifth through eighth decades of age, for an age-and sex-stratified random sample of n=1000, all of western European descent). No subjects were enrolled after study initiation. In 1995, 826 subjects participated in the first quinquennial re-examination and DNA samples for genotyping were available in 816 individuals. During follow-up from 1995 to 2010, detailed information about fatal and nonfatal newonset CVD was carefully collected. Follow-up was 100% complete for clinical endpoints, which was made possible by the extremely low population mobility of 0.2% in the Bruneck area. The study protocol was approved by the ethics committees of Bolzano and Verona and conformed to the Declaration of Helsinki. All study subjects provided written informed consent. Risk factors were assessed by means of validated standard procedures as described previously. 15, 19 At the baseline and follow-up examinations in 1995, 2000, 2005, and 2010, venous blood was sampled in the morning after an overnight fast for laboratory measurements, including fasting plasma glucose and HbA 1c (Diabetes Control and Complications Trial-aligned assay; equipment and reagents from BioRad, Milan, Italy, at both baseline and follow-up examinations). In accordance with the study of Cahill et al, HbA 1c was dichotomized according to a cut-off of 6.5% (48 mmol/mol, International Federation of Clinical Chemistry units).
Diabetes mellitus was coded present for subjects with fasting glucose levels ≥7 mmol/L (≥126 mg/dL) or a medical record confirmed prediagnosis of definite disease status. Based on the literature 14 we anticipated few subjects with the Hp 1-1 genotype and, to maximize statistical power, decided prior to analysis to pool the Hp 1-1 and 2-1 genotypes, forming a group of Hp1 allele carriers, which is a common approach. 14 We ascertained leisure time-related physical activity by a standardized questionnaire 20 rating the intensity of activities according to the compendium of physical activities 21 and calculated average metabolic equivalent hours per week to estimate long-term physical activity. We assessed food intake by a standardized food-frequency questionnaire (FFQ) based on the gold standard Harvard FFQ by Willett and colleagues and adapted the FFQ to the dietary peculiarities in the survey area. We validated our FFQ with a dietician-supervised shortterm assessment of food intake. Validity was high and similar to that previously found for the same FFQ in other populations. 22 The Alternative Healthy Eating Index (AHEI) was calculated from these data as a quantitative measure of healthy dietary behavior. 23 Body mass index (BMI) was calculated as weight in kilograms over height in meters squared.
Haptoglobin Genotyping
The Haptoglobin genotype was determined by PCR as described previously 24 
Endpoints
The composite CVD endpoint included incident fatal and nonfatal myocardial infarction and stroke. Presence of myocardial infarction was assessed by World Health Organization criteria (definite disease status), 25 while stroke was classified according to the criteria of the National Survey of Stroke. 26 Events were ascertained by careful review of medical records provided by general practitioners, death certificates, and Bruneck Hospital files. A major advantage of the Bruneck Study is that virtually all inhabitants of Bruneck are referred to 1 local hospital that cooperates closely with the general practitioners. This allows retrieval of complete medical information. Subjects who had experienced CVD events before the study baseline in 1995 were included in the main analysis and observed for recurring incident CVD between 1995 and 2010, and excluded in a sensitivity analysis.
Statistical Analysis
Hardy-Weinberg equilibrium was tested by a permutationbased chi-squared test. Associations with incident CVD were assessed by Cox proportional hazards regression with HbA 1c or diabetes status (present/absent) as time-varying covariates in a granularity of 5 years. This approach relates the most current measure of glycemic exposure to incident CVD and avoids potential confounding due to reliance on a single baseline measurement. Effect modification of Hp 2-2 by HbA 1c category was tested using an appropriate interaction term. To simultaneously obtain marginal effects of Hp genotype for both HbA 1c groups as well as the interaction effect, a linear combination of model parameters was made. The proportional hazards assumption was tested by computing the correlation coefficient of survival time with scaled Schoenfeld residuals and was met. Base models were adjusted for age and sex (model 1) and 2 multivariable models with progressive adjustment were employed (model 2: additionally for current smoking, systolic blood pressure, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol; model 3: additionally for metabolic equivalent hours, alternative healthy eating index, statin use, and body mass index). Last observation carried forward or next observation carried backward imputation reduced the proportion of missing HbA 1c values from 5.9% to 0.4%.
Sensitivity analyses excluded subjects with missing HbA 1c values, used age as the time scale and focused on individual disease endpoints. All tests were 2-sided and P values smaller than 0.05 were considered significant. All analyses were performed using the R statistical package.
Results
Characteristics of the study population are shown in Table 1 Sensitivity analyses excluding subjects with missing HbA 1c values, excluding subjects with prior CVD or using age as the time scale (instead of time-on-study) yielded similar findings (Table 2) We also investigated differences in blood lipids by Hp genotype. Total cholesterol and LDL cholesterol were higher in Hp 2-2 subjects than in those with other genotypes when adjusting for age, sex, and body mass index (P=0.008 and P=0.016, respectively). These results are shown in Table 3 .
Discussion
Our data do not confirm the recent report of Cahill and colleagues that identified the Hp 2-2 genotype as a cardiovascular risk factor among subjects with elevated HbA 1c. Part of this discrepancy may derive from differences in study design and population. Cahill used a nested case-control design with 1:1 matching in female nurses with 14-year follow-up for their main analysis, and data from a clinical trial with 18 months of follow-up performed in type 2 diabetic patients for confirmation, whereas we used a 15-year prospective observational design on a random sample of the general population. Importantly, Cahill excluded participants with prior CVD, which we did not, and used a coronary heart disease (CHD) endpoint, while we used a compound of myocardial infarction and stroke in the main analysis. Another potential explanation for the discrepancy between our and Cahill's results is survival bias. However, we observed a higher frequency of Hp 2-2 genotype (48%) than most previous studies in Caucasians did (36 to 40%), 2, 3, 14, 27 which is the opposite of what would be expected in the presence of a survival disadvantage. Furthermore, genotypes were in HardyWeinberg equilibrium overall as well as in the younger and older half of our sample separately, which argues against the existence of significant survival bias.
14
Our results are unexpected because Hp 2-2 as a risk genotype among diabetic subjects would be backed by a biologically plausible rationale based on its weaker antioxidant properties.
2,28-30 However, not all aspects of this rationale are fully consistent. In particular, the Hp 2-2-Hb compared with the Hp 1-1-Hb complex has been reported to be taken up into macrophages via the CD163 scavenger receptor at higher 31 as well as at lower 4 rates. No differences in Hb binding and antioxidant potency between purified human Hp 1-1 and Hp 2-2 were recently found in an animal model of hemolysis. 32 In addition, Hp has numerous functions apart from Hb clearance, taking part in inflammatory pathways (prostaglandin synthesis, cathepsin B activity, endothelium-dependent vasodilation) 3, 33 and interfering with the functions of immune cells. 34, 35 Hp phenotypes differ in some of these functions. 3 Notably, Hp 2-2 is the most angiogenic phenotype, 36 which was discussed as an explanation for longer walking distance in Hp 2-2 peripheral vascular disease patients (P<0.05), 7 and Hp 1-1 was linked to decreased endothelial repair potential in lacunar stroke patients. 37 In this study, subjects with the Hp 2-2 genotype had elevated total and LDL cholesterol (Table 3) , which has been reported previously. 38, 39 This finding may be explained by the close genetic linkage between Hp genotype and a single nucleotide polymorphism in the gene encoding haptoglobinrelated protein, which is associated with levels of total but not HDL cholesterol via apolipoprotein L. 27 However, adjusting for LDL levels did not appreciably change risk estimates (Table 2) , which argues against the possibility that CVD risk differences due to Hp genotype are mediated by LDL levels.
Strengths of the present study include the virtually complete, long-term follow-up, detailed characterization of the study population and repeated measurements of HbA 1c . Another major strength of the Bruneck Study is its high representativity for the general population. It comprises predominantly low-and medium-risk individuals, which are of the foremost public health interest since most CVD events happen in such individuals. 40 One downside of this is a comparatively low prevalence of elevated HbA 1c , which precludes more complex analyses like 3-way interactions between HbA 1c , diabetes, and Hp genotype. It merits attention that while we found a trend towards protective effects of the Hp 2-2 genotype among subjects with elevated glycohemoglobin, this result was statistically not significant, and hazardous effects would also be compatible with our data. The largest hazardous effect that we cannot refute at the a=0.05 level is a risk elevation of %26% (multivariable model 2, Figure) . Larger studies are required to draw definite conclusions. In summary, this study does not confirm that the Hp 2-2 genotype is associated with a higher CVD risk in subjects with elevated HbA 1c .
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